 This is a cluster-randomized, open label interventional study to determine the feasibility of achieving significant reduction in malaria cases in military encampments on the Thai-Cambodian border. The study will compare the effectiveness, safety, and tolerability of monthly malaria prophylaxis MMP to monthly focused screening and treatment FSAT. This study will thus investigate the effectiveness of two potential interventions for malaria elimination. Subjects in the monthly malaria prophylaxis MMP arm will receive a standard 3-day treatment course of dihydroartemisinin-piperaquine on months 1, 2 and 3 and weekly low-dose primaquine 22.5mg for 12 weeks. Volunteers in the focused screening and treatment FSAT arm will be screened monthly and then treated for malaria following national treatment guidelines. For G6PD-deficient volunteers in the FSAT arm, primaquine will be administered weekly 45mg for 8 weeks as radical curative andor presumptive anti-relapse therapy. For G6PD normal volunteers with vivax infection, primaquine will be administered daily 15mg for 14 days. All FSAT volunteers with confirmed P. falciparum infection will receive a single, low dose 15mg Primaquine as a P. falciparum transmission-blocking agent. The incremental benefit of an insecticide treated uniform ITU will also be assessed as a single-blind sham-controlled intervention in addition to personal protective measures currently employed by the RCAF. Volunteers will be followed monthly for a total of 6 months, to determine the proportion remaining malaria-free on day 180 following enrollment. 